Clinical trials: Stage II Skin Cancer
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in treating patients with HER2 positive stage…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT04108858
- Testing
- Copanlisib, Pertuzumab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Contralateral Breast Cancer
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may improve the ability to detect cancer in the unaffected breast of women recently diagnosed with unilateral breast cancer.
- Trial name
- ACRIN-6667 (NCT00058058)
- Testing
- MRI
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 1,007 people
- Sponsor
- American College of Radiology Imaging Network
Breast Cancer
Xeloda (Capecitabine) and External Beam Radiation
The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy.
- Trial name
- NCT00916578
- Testing
- Radiation Therapy, Capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms, Breast Cancer
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
The purpose of this study is to assess if docetaxel and cytoxan can shrink the size of your breast tumor and allow you to preserve your breast or have less extensive surgery on your breast.
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of the Breast
- Trial name
- NCT00832338
- Testing
- Docetaxel with Cytoxan, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Breast Cancer, Triple Negative Breast Cancer
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
- Trial name
- PERSEVERE (NCT04849364)
- Testing
- Capecitabine, Talazoparib, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Bryan Schneider, MD
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer, Esophageal Cancer
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Conditions
- Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms
- Trial name
- NCT01624090
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Carcinoma
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a study to test an alternative dosing schedule of palbociclib. With the current three-week on and one week off schedule, a significant number of patients develop grade 3 or higher degree of…
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
- Trial name
- NCT03007979
- Testing
- Palbociclib, Letrozole, Fulvestrant
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
This research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer. The drugs involved in this study are: Nivolumab (Opdivo ®) Ipilimumab (Yervoy ®)
- Trial name
- NCT03789110
- Testing
- Nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, Breast Neoplasms
Vaccination of Triple Negative Breast Cancer Patients
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast…
- Trial name
- NCT02938442
- Testing
- P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Arkansas
Breast Neoplasm
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients: trastuzumab (Herceptin) epirubicin…
- Trial name
- NCT00270894
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Accelerated Community Oncology Research Network
Breast Neoplasms
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
This is a phase II, open-label, multicenter, pilot study of the safety and efficacy of two Docetaxel-based regimens plus bevacizumab for the adjuvant treatment of participants with node positive or high risk node negative breast…
- Trial name
- NCT00446030
- Testing
- Docetaxel, Doxorubicin, Carboplatin
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Sanofi
Breast Cancer, Stage I Breast Cancer
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
This phase II trial is studying how well vorinostat works in treating women who are undergoing surgery for newly diagnosed stage I, stage II, or stage III breast cancer.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT00262834
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer.
- Trial name
- NCT00894504
- Testing
- Panitumumab, Carboplatin, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 71 people
- Sponsor
- SCRI Development Innovations, LLC
Malignant Melanoma
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
The investigators have observed that many patients who had received high dose Interleukin-2 (IL2) and failed to respond to it but who then go immediately to temozolomide seemed to enjoy extremely good responses which seem better…
- Trial name
- NCT01124734
- Testing
- Interleukin-2, Temozolomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Milton S. Hershey Medical Center
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
This phase II trial studies how well everolimus with or without trastuzumab works in treating patients with breast cancer that has not responded to hormone therapy and has spread from where it started to other places in the body.
- Trial name
- NCT00912340
- Testing
- Everolimus, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Metastatic Breast Cancer
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
This randomized, double blind, placebo controlled trial will evaluate the impact of adding everolimus to the combination of weekly paclitaxel plus bevacizumab in the first-line treatment of women with HER2-negative metastatic…
- Trial name
- NCT00915603
- Testing
- Everolimus, Bevacizumab, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone…
- Trial name
- NCT02764541
- Testing
- Letrozole, Tamoxifen, Palbociclib
- Where
- 11 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.